<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02140918</url>
  </required_header>
  <id_info>
    <org_study_id>2013-004794-27</org_study_id>
    <nct_id>NCT02140918</nct_id>
  </id_info>
  <brief_title>Fludrocortisone in Healthy Volunteers (AFLUCO4)</brief_title>
  <acronym>AFLUCO4</acronym>
  <official_title>Hemodynamic and Biological Effects of 3 Increasing Doses of Fludrocortisone in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fludrocortisone, in association with hydrocortisone, has demonstrated an improvement in
      survival in septic shock patients with relative adrenal insufficiency. However, the utility
      of low doses of steroids and in particular of mineralocorticoids in septic shock is still
      discussed.

      The purpose of the investigators study is to investigate the effects of 3 increasing doses of
      fludrocortisone (100 μg, 200 μg, 400 μg) in order to determine which dose allows the best
      pressor response to phenylephrine in healthy volunteers, and simultaneously assess their
      respective hemodynamic and biological effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a previous study (AFLUCO2) in healthy volunteers with saline-induced hypoaldosteronism,
      the investigators found that single doses of both hydrocortisone and fludrocortisone induced
      a significant decrease in the pressor response to phenylephrine, probably due to a rapid
      non-genomic vasodilatory mechanism, and that these effects were additive.

      The investigators also showed that, at the doses used in septic shock, hydrocortisone induced
      more pronounced mineralocorticoid effects than fludrocortisone and also induced systemic
      hemodynamic effects whereas fludrocortisone did not.

      The investigators now want to perform a dose-response study under normal conditions (ie
      without saline-induced hypoaldosteronism) and after repeated administrations, to determine
      the optimal dose of fludrocortisone that allows an increase in the pressor response to
      phenylephrine and to characterize its concomitant hemodynamic and biological effects.

      This placebo-controlled, randomized, double-blind, cross-over, 4-periods (fludrocortisone 100
      μg/day, 200 μg/day, 400 μg/day, or placebo) study aims to investigate hemodynamic and
      biological effects of fludrocortisone administered orally during 5 days, in healthy
      volunteers.

      Each period will be separated from the next one by a washout interval of at least 14 days.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phenylephrine mean blood pressor dose-response relationship.</measure>
    <time_frame>1.5 hour after fludrocortisone administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac systolic and diastolic function assessed par transthoracic echocardiography during phenylephrine administration</measure>
    <time_frame>between 1.5 and 2.5 hours after fludrocortisone administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic hemodynamic parameters</measure>
    <time_frame>30min before and 1h, 2h, 3h, 4h, 5h, 6h after fludrocortisone administration</time_frame>
    <description>Systolic, diastolic and mean arterial pressures, heart rate, peripheral pulse pressure, cardiac output, stroke volume, systemic vascular resistances</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial stiffness : carotid-femoral pulse wave velocity</measure>
    <time_frame>30min before and 1h, 2h, 3h, 4h, 5h, 6h after fludrocortisone administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central aortic hemodynamic parameters</measure>
    <time_frame>30min before and 1h, 2h, 3h, 4h, 5h, 6h after fludrocortisone administration</time_frame>
    <description>Aortic systolic, diastolic and mean arterial pressures, central pulse pressure, central pressure augmentation index (AIx)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma parameters</measure>
    <time_frame>30min before and 1h, 2h, 3h, 4h, 5h, 6h after fludrocortisone administration</time_frame>
    <description>Blood electrolytes, urea, creatinine, glucose, renin, aldosterone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary parameters</measure>
    <time_frame>30min before and 2h, 4h, 6h after fludrocortisone administration</time_frame>
    <description>Diuresis, urinary electrolytes, urea, creatinine, glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Just before and 5min, 10min, 20min, 30min, 1h, 1h30, 2h, 3h, 4h, 5h, 6h after fludrocortisone administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma half-life of fludrocortisone</measure>
    <time_frame>Just before and 5min, 10min, 20min, 30min, 1h, 1h30, 2h, 3h, 4h, 5h, 6h after fludrocortisone administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Clearance</measure>
    <time_frame>Just before and 5min, 10min, 20min, 30min, 1h, 1h30, 2h, 3h, 4h, 5h, 6h after fludrocortisone administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution</measure>
    <time_frame>Just before and 5min, 10min, 20min, 30min, 1h, 1h30, 2h, 3h, 4h, 5h, 6h after fludrocortisone administration</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Fludrocortisone 100 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 μg/day (25 µg four times daily) of fludrocortisone during 5 days
Investigations the sixth day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fludrocortisone 200 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 μg/day (50 µg four times daily) of fludrocortisone during 5 days
Investigations the sixth day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fludrocortisone 400 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 μg/day (100 µg four times daily) of fludrocortisone during 5 days
Investigations the sixth day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (four times daily) during 5 days
Investigations the sixth day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludrocortisone 100 μg</intervention_name>
    <description>Fludrocortisone 100 μg/day</description>
    <arm_group_label>Fludrocortisone 100 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludrocortisone 200 μg</intervention_name>
    <description>Fludrocortisone 200 μg/day</description>
    <arm_group_label>Fludrocortisone 200 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludrocortisone 400 μg</intervention_name>
    <description>Fludrocortisone 400 μg/day</description>
    <arm_group_label>Fludrocortisone 400 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men aged 20 to 25 years

          -  Body Mass Index between 20 kg/m² and 25 kg/m²

          -  Nonsmoker since at least 6 months

          -  Normal clinical examination, electrocardiogram and transthoracic echocardiography

          -  Normal routine biological parameters

          -  Written informed consent

        Exclusion Criteria:

          -  History of significant allergy

          -  Resting heart rate &lt; 50 bpm

          -  Subjects with abnormal hepatic or renal function, or cardiovascular, pulmonary,
             endocrine or psychiatric disease

          -  Ongoing medication during the study

          -  Alcohol consumption more than 30g/day or drug addiction

          -  Exclusion period mentioned on the national registry for clinical trials volunteers.

          -  Subject under legal protection
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Laviolle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre d'Investigation Clinique Inserm 1414, Service de Pharmacologie Clinique, Hôpital de Pontchaillou</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Bellissant, MD, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre d'Investigation Clinique Inserm 1414, Service de Pharmacologie Clinique, Hôpital de Pontchaillou</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno Laviolle, MD, PHD</last_name>
    <phone>33 (0)2.99.28.96.68</phone>
    <email>bruno.laviolle@chu-rennes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Laviolle, MD, PHD</last_name>
      <phone>33 (0)2.99.28.96.68</phone>
      <email>bruno.laviolle@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno Laviolle, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabrice Lainé, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erwan Donal, MD, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2014</study_first_submitted>
  <study_first_submitted_qc>May 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2014</study_first_posted>
  <last_update_submitted>October 28, 2015</last_update_submitted>
  <last_update_submitted_qc>October 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fludrocortisone</keyword>
  <keyword>Mineralocorticoids</keyword>
  <keyword>Hemodynamics</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

